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BACKGROUND: House dust contains many organic contaminants that can compete with the thyroid hormone (TH) thyroxine (T4) for binding to trans-
thyretin (TTR). How these contaminants work together at levels found in humans and how displacement from TTR in vitro relates to in vivo T4-TTR
binding is unknown.
OBJECTIVES: Our aims were to determine the TTR-binding potency for contaminant mixtures as found in house dust, maternal serum, and infant se-
rum; to study whether the TTR-binding potency of the mixtures follows the principle of concentration addition; and to extrapolate the in vitro TTR-
binding potency to in vivo inhibition levels of T4-TTR binding in maternal and infant serum.
METHODS: Twenty-five contaminants were tested for their in vitro capacity to compete for TTR-binding with a fluorescent FITC-T4 probe. Three
mixtures were reconstituted proportionally to median concentrations for these chemicals in house dust, maternal serum, or infant serum from Nordic
countries. Measured concentration–response curves were compared with concentration–response curves predicted by concentration addition. For each
reconstituted serum mixture, its inhibitor–TTR dissociation constant (Ki) was used to estimate inhibition levels of T4-TTR binding in human blood.
RESULTS: The TTR-binding potency of the mixtures was well predicted by concentration addition. The ∼ 20% inhibition in FITC-T4 binding observed for
the mixtures reflecting median concentrations in maternal and infant serumwas extrapolated to 1.3% inhibition of T4-TTR binding in maternal and 1.5% in
infant blood. For nontestedmixtures reflecting high-end serum concentrations, these estimates were 6.2% and 4.9%, respectively.
DISCUSSION: The relatively low estimated inhibition levels at median exposure levels may explain why no relationship between exposure to TTR-
binding compounds and circulating T4 levels in humans has been reported, so far. We hypothesize, however, that 1.3% inhibition of T4-TTR binding
may ultimately be decisive for reaching a status of maternal hypothyroidism or hypothyroxinemia associated with impaired neurodevelopment in chil-
dren. https://doi.org/10.1289/EHP5911
Introduction
Over the past decade, awareness has increased that house dust is
a matrix containing complex mixtures of contaminants. Most of
these contaminants originate from the use and wear of household
products and building materials; indoor activities such as cook-
ing, smoking, and incineration of (household) products; and the
intrusion of outdoor material (Mercier et al. 2011). In an inven-
tory of contaminants reported in house dust, Zhang et al. (2015)
found 485 organic compounds, including alkyl-phenols and their
ethoxylates, phthalates, parabens, musks, perfluoroalkyl substances
(PFASs), brominatedflame retardants (BFRs) including polybromi-
nated diphenyl ethers (PBDEs), organophosphorous flame retard-
ants (OPFRs), polychlorinated biphenyls (PCBs), polyhalogenated
dibenzo-p-dioxins and dibenzofurans (PXDD/Fs) polycyclic aro-
matic hydrocarbons, chlorinated benzenes, polychlorinated naph-
thalenes, organo-siloxanes, volatile organic compounds, ultraviolet
(UV)-filter related chemicals, biocides, and pesticides.
Indoor exposure to house dust contaminantsmay occur through
inhalation, dermal contact, and ingestion. The importance of the
latter route has been mainly demonstrated for PBDEs. The
contribution of house dust ingestion to the total PBDE intake in
adults appears to be in the same order of magnitude as the contribu-
tion of dietary exposure, although estimates differ considerably
between countries (Besis and Samara 2012; SK Kim et al. 2016).
More importantly, these studies concluded that house dust inges-
tion is the major route of PBDE exposure for toddlers, who have
lower dietary intake but higher house dust ingestion than adults
due to their relatively long residence time on the floor and frequent
hand-to-mouth contact. Given the high number of contaminants
demonstrated in house dust, it is to be expected that house dust
ingestion especially by toddlers may be an underestimated route of
human exposure to compounds other than PBDEs (De Boer et al.
2016).
Many house dust contaminants are known to be thyroid-
hormone (TH) disrupting compounds (Zhang et al. 2015), such
as phenols, phthalates, parabens, PFASs, PBDEs, OPFRs, PCBs,
PXDD/Fs, UV filters, and biocides. Some of these chemicals
have been reported to antagonize thyroid receptor (TR) activity
(Klopcic et al. 2016; Kollitz et al. 2018; Zhang et al. 2016).
Others have been shown to activate the nuclear receptors preg-
nane X receptor (PXR), constitutive androstane receptor (CAR)
(Kretschmer and Baldwin 2005), or arylhydrocarbon receptor
(AhR) (Denison and Nagy 2003), thereby inducing the expres-
sion and activity of uridine diphosphate glucuronosyltransferase
(UGT) isoforms 1A1 and 1A6 (Shelby and Klaassen 2006),
which are responsible for an increased glucuronidation (Roos
et al. 2011; Vansell and Klaassen 2002) and subsequent hepatic
clearance (Liu et al. 1995) of TH. Still others have been shown to
inhibit the sodium iodide symporter (NIS) (Hallinger et al. 2017;
Wang et al. 2018) or thyroid peroxidase (TPO) (Paul et al. 2014),
which are involved in TH synthesis. In the present study, we
focus on the TH distributor protein transthyretin (TTR) as a target
for TH disrupting compounds. Together with TH binding globu-
lin (TBG) and albumin (ALB), TTR is one of the three plasma
carrying proteins transporting TH from the thyroid gland to the
peripheral (target) tissues. Although triiodothyronine (T3) is the
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actual active form of TH, these distributor proteins have a higher af-
finity for its precursor thyroxine (T4) (Salvatore et al. 2016). Many
xenobiotic substances, including house dust contaminants, are capa-
ble of competing with T4 for binding to TTR (Weiss et al. 2015;
Zhang et al. 2016). As a consequence, diminished amounts of TTR-
bound T4 is stored in the blood plasma and correspondingly larger
amounts of free T4 are available for biliary elimination via hepatic
uptake and conjugation, causing a decrease in free and total plasma
T4 levels, as observed in rodents exposed to TTR-binding com-
pounds (Darnerud et al. 1996; Hallgren and Darnerud 2002). T4
deficiency has been implicated in neurodevelopmental effects on
cognition in rodents (Taheri et al. 2018) and humans (Korevaar et al.
2016). Moreover, TTR-binding PCB metabolites were shown to
accumulate in blood plasma of laboratory rats (Bergman et al.
1994), free-ranging polar bears (Gutleb et al. 2010), and human pop-
ulations (Athanasiadou et al. 2008; Park et al. 2008) and may ulti-
mately be transported across the placenta where they have been
demonstrated in fetal rat brain (Meerts et al. 2002) and in human
cord blood (Park et al. 2008), most likely due to TTR-mediated
transport. It cannot be excluded that this transport route also holds
for other persistent TTR-binding compounds.
To our knowledge, the contribution of multiple chemicals pres-
ent in house dust to displacing T4 from TTR has not been investi-
gated. Accordingly, the goal of the present study was a) to
determine the TTR-binding potency of complex mixtures of house
dust contaminants representing the composition as found in human
blood and in house dust; b) to study whether the TTR-binding po-
tency of the complex mixtures could be predicted by weighing the
concentration of each individual constituent of the mixture for its
TTR-binding potency, according the principle of concentration
addition; and c) to extrapolate the TTR-binding capacity of the
mixtures in an in vitro binding assay to in vivo inhibition levels of
T4-TTR binding in humanmaternal and infant blood.
Altogether, a set of 25 compounds was selected and tested
individually for their capacity to bind to TTR in a competitive
binding assay. In addition, three different mixtures were reconsti-
tuted reflecting the composition of the selected chemicals based
on median concentrations reported in house dust, maternal serum,
or in serum from cord blood/infants (hereafter referred to as
infants). These mixtures were also tested in the TTR-binding
assay to confirm that the principle of concentration addition holds
for such complex mixtures. In addition, the mixture experiments
allowed us to determine a margin of exposure between the actual
median mixture concentration in serum from infants and mothers
on the one hand and the observed effect levels in the in vitro
TTR-binding assay on the other hand. More importantly, the in
vitro TTR-binding potencies of the mixtures were extrapolated to
actual in vivo TTR-binding potencies in maternal or infant blood,
taking into account the binding of TH to the other two plasma
distributor proteins, TBG and ALB. As such, the concentrations
in human plasma of TTR-binding inhibitors were calculated into
predicted effect levels in humans.
Material and Methods
Test Compound Selection
Test compounds were selected based on three different criteria:
1. The compounds should be present in house dust, or—in
the case of metabolites—their parent compound should be
present in house dust. To meet this criterion, all selected
compounds or their parent compounds should be listed in
the inventory of 485 house dust contaminants made by
Zhang et al. (2015).
2. The TTR-binding capacity of the compounds or theirmetab-
olites should have been experimentally confirmed. Weiss
et al. (2015) compiled a database of 144 compounds capable
of competing with TH for TTR-binding. As was to be
expected based on structural similarity with TH,many TTR-
binding compounds were halogenated phenols (including
metabolites of PBDEs, PCBs, and PXDD/Fs), but PFASs
and other (mainly halogenated) compounds were also iden-
tified as TTR-binders.
3. Their concentration in dust, maternal serum, or cord blood/
infant serum should be known. For compounds meeting the
first two criteria, data onmedian levels in dust, inmaternal se-
rum, and in cord blood/infant serum were collected in 2016
from Swedish studies or alternatively European, preferably
Nordic, studies reported in the open literature. The selection
of Swedish studies was based on the fact that the present
study was performed within a Swedish research project
called MiSSE (Mixture aSSessment of Endocrine disrupting
compounds with emphasis on the TH system). MiSSE has
determined concentrations formany house dust contaminants
in Swedish household dust. Many of these concentrations
were used in the present study. To obtain geographic corre-
spondence between chemical profiles in house dust and
human serum, the present study gave preference to the utili-
zation of Swedish, or elseNordic, serum levels.
The set of 25 selected test chemicals consisted of the follow-
ing compounds: perfluorohexanoic acid (PFHxA), perfluoro-
heptanoic acid (PFHpA), perfluorooctanoic acid (PFOA), per-
fluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA),
perfluoroundecanoic acid (PFUnDA), perfluorobutane sulfonic
acid (PFBS), perfluorohexane sulfonic acid (PFHxS), perfluor-
ooctane sulfonic acid (PFOS), perfluorooctane sulfonamide
(FOSA), propyl 4-hydroxybenzoate (propylparaben), 4-nonylphe-
nol, pentachlorophenol, 5-chloro-2-(2,4-dichlorophenoxy)phenol
(triclosan), tetrabromo-bisphenol-A (TBBPA), 2,4,6-tribromophe-
nol (2,4,6-TBP), 2,20,4,40-tetrabromodiphenyl ether (BDE-47) and
its metabolites 5-OH-2,20,4,40-tetrabromodiphenyl ether (5-OH-
BDE-47) and 6-OH-2,20,4,40-tetrabromodiphenyl ether (6-OH-
BDE-47), 2,20,4,40,5-pentabromodiphenyl ether (BDE-99) and
its metabolite 60-OH-2,20,4,40,5-pentabromodiphenyl ether (60-
OH-BDE-99), 2,3 0,4,4 0,5-pentachlorobiphenyl (CB-118) and
its metabolite 4-OH-2,3,3 0,4 0,5-pentachlorobiphenyl (4-OH-
CB-107), and 2,2 0,4,4 0,5,5 0-hexachlorobiphenyl (CB-153) and
4-OH-2,2 0,3,4 0,5,5 0,6-heptachlorobiphenyl (4-OH-CB-187). All
test compounds, together with their supplier, Chemical Abstract
Service number, and median or high-end (i.e., maximum or 95th
percentile) concentrations reported in house dust, maternal and
infant blood from Nordic countries are listed in Excel Tables S1
and S2. These Tables further specify whether infant concentra-
tions refer to concentrations in cord blood or in children and pro-
vide references to the original publications.
Test Solutions and Mixture Reconstitution
Formost of the selected compounds, stock solutions (10 or 100 mM)
and subsequent dilution series were prepared in tetrahydrofuran
(THF). To test the individual compounds in the bioassay, stock solu-
tions in dimethyl sulfoxide (DMSO) were prepared by the addition
of 200 lL of DMSO to 200 lL of the THF solutions followed by
THF evaporation under a gentle nitrogen flow.To reconstitute amix-
ture, for each individual compound a precalculated volume corre-
sponding to its ultimate molar fraction in the mixtures was taken
from the THF stock or its respective dilution. After pooling these
THF volumes for all compounds, 500 lL of DMSO was added, fol-
lowed by THF evaporation. Perfluoroalkyl sulfonic acids (PFSAs)
were not dissolved in THF, given the polymerization reaction of
THF with highly acidic short-chained PFSAs (Pruckmayr and Wu
1978), also observed for PFBSs in this study. Instead, PFSAs were
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directly dissolved and further diluted in DMSO. During mixture
reconstitution, PFSAs (in DMSO) were added last. The ultimate
500-lL volume of DMSOadded to themixture was adjusted accord-
ingly. All DMSO stocks of individual compounds andmixtures were
further diluted in DMSO for dose–response testing in the bioassay.
During mixture reconstitution, all pipetting steps were weighed,
allowing the exact determination of the concentrations in the test
mixtures. These actual concentrations (see Table S1) based on
weights—and not the originally targeted nominal concentrations—
were further used in data analyses. Differences between the actual
and the targetedmolar contributions to themixturewere atmaximum
2.2% but were <1% in 95% of the cases.
Dust Extraction
To determine the contribution of the compounds tested in the pres-
ent study to the overall TTR-binding potency in house dust, the
extract of a well-characterized dust sample, for which many analyti-
cal data were available, was tested in the TTR-binding assay. For
this purpose, the Standard Reference Material® 2585 (SRM2585)
dust sample was purchased from the National Institute of Standards
and Technology (NIST) and extracted according to Van den Eede
et al. (2012). Briefly, 70 mg of dust was extracted three times with
an isohexane:acetone 3:1 (vol/vol) mixture by vortexing followed
by ultrasonication. After each consecutive extraction, dust was pel-
leted by centrifugation and the supernatant was pooled. The solvent
was evaporated under a gentle nitrogen flow and the extracts were
transferred to 200 lL ofDMSO.
TTR-Binding Assay
The TTR-binding potency of the individual compounds, the recon-
stitutedmixtures, and the SRM2585 extract was tested in a compet-
itive binding assaymaking use of a fluorescent conjugate of T4 and
fluorescein 5-isothiocyanate (FITC). The method originally devel-
oped by Ren and Guo (2012) was previously transformed into a
96-well plate format (Ouyang et al. 2017) and further modified and
optimized (Leusch et al. 2018) in our laboratory. The FITC-T4 con-
jugate shows high fluorescence when its T4 group is bound to TTR.
In the presence of competitive TTR-binding compounds, a decrease
in bound FITC-T4 can be quantified as a decrease in fluorescence,
which is due to the intramolecular quenching of the fluorescein group
by the free T4 group.
The FITC-T4 conjugate was synthesized as described by Ren
and Guo (2012). Briefly, 0:5 mL of 20-mg=mL FITC was reacted
with 1:0 mL of 10-mg=mL T4 (both dissolved in a mixture of
9 mL pyridine, 1:5 mL ultrapure water, and 0:1 mL triethylamine)
for 1 h at 37°C. The FITC-T4 conjugate was consecutively precipi-
tated, centrifuged, washed, centrifuged, redissolved, and purified
on a Sephadex® LH20 column. After elution with ultrapure water,
the FITC-T4 concentrationwas determined photospectrometrically
using a molar extinction coefficient of e=7:8× 104 M−1cm−1
(Ren and Guo 2012). The FITC-T4 solution was aliquoted and
stored at−80C.
All TTR-binding experiments were performed in black 96-well
polystyrene nonbinding plates (Greiner Bio-One). Given the mini-
mized adsorption to the wall of these well plates, nominal concen-
trations of FITC-T4, TTR, and test compounds could be used in the
data analysis as total concentrations of ligand, binding protein, and
inhibitor, respectively. All incubations were performed for 2 h at
4°C (on ice) in a final volume of 200 lL Tris-HCl buffer (pH 8.0).
Fluorescence [expressed as arbitrary fluorescence units (AFUs)]
wasmeasured at kex = 490 nm and kem = 518 nm.
The dissociation constant Kd of the FITC-T4-TTR complex was
determined in a saturation experiment with a fixed concentration of
TTR (30 nM), various concentrations of FITC-T4 (ranging from 0
to 1,000 nM), and no inhibitor. Competitive TTR-binding assays
were performed by incubating human TTR (30 nM) with 110 nM
of FITC-T4 in the presence of test compounds, reference compound
T4, or carrier solvent control (1%DMSO). For each incubation with
TTR, a parallel incubation was performed without TTR to correct
for background fluorescence of the unbound FITC-T4. In the com-
petitive binding experiments, these control incubations were also
used to check for possible quenching of FITC-T4 fluorescence by
the test compounds and for autofluorescence of the test compounds
themselves, neither of which was observed. Altogether, on each 96-
well plate three different compounds or mixtures were tested in
duplicate with and without TTR in a concentration series of seven
concentrations and a solvent control. Each compound, each recon-
stitutedmixture, and the SRM2585 dust extract was tested in two in-
dependent experiments, except for the reference compound T4,
which was tested in 21 experiments altogether. All experiments
were performedwithin a period of 4weeks.
Background Correction
All fluorescence measurements were corrected for protein-
independent fluorescence by subtracting the measured fluores-
cence in the absence of protein from the measured fluorescence
in the presence of protein. The obtained corrected fluorescence
(Fc) is directly proportional to the concentration of the protein–
ligand complex [PL] as demonstrated in “S1.2 Corrected fluo-
rescence is proportional to [PL]” in the Supplemental Material,
based on the basic principles of protein–ligand binding in the
presence of a competitive inhibitor described in “S1.1 Basic
principles of protein-ligand binding in the presence of a com-
petitive inhibitor.”
Kd Estimation
Fc values of the saturation experiment, expressed in AFUs, could
consequently be described as a function of the total ligand con-
centration (LT )
Fc = a× PL½ 
= a×
Kd + PT½ + LT½ ð Þ−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi





with a being the ratio between Fc and [PL], [PT ] is the total protein
concentration (i.e., ½TTR=30 nM), and [LT ] is the total ligand
concentration ranging from 0 to 1,000 nM FITC-T4 in the satura-
tion experiment. Parameters a and Kd were estimated by nonlinear
regression between [LT ] and Fc. The theory behind Equation 1 and
its derivation have been described in detail in “S1.3Kd assessment”
in the SupplementalMaterial, based onNeubig (2011).
Concentration–Response Analysis
For the competitive binding experiments, the correctedfluorescence
measurements were used to fit concentration–response curves and
derive the concentration causing 20% and 50% inhibition of TTR-
binding by FITC-T4 (IC20 and IC50, respectively). Similarly, con-
centration–response curves with corresponding IC20 and IC50 val-
ues were derived for the mixtures, with mixture concentration (cmix)
being expressed as the total molar concentration of TTR-binding
compounds in proportions reflecting their median concentrations in
maternal serum, infant serum, and house dust reported in Nordic
countries. For the SRM2585 dust extract, concentration–response
curves with corresponding IC20 and IC50 values were derived,
expressed as the corresponding dust concentration in the assay (in
grams of dust per liter).
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Concentration–effect data analysis for individual compounds
and mixtures was performed by a best-fit approach (Scholze et al.
2001) where various nonlinear regression models were fitted to
the same pooled data set and the model that described data best
was selected. In case of a significant inter-study data variation,
experiment was included as random factor in the best-fit data
analysis (nonlinear mixed effect model (see Altenburger et al.
2018 for more detail).
The effects of the reconstituted mixtures were predicted accord-
ing to the principle of concentration addition (CA) under the
assumption of noninteraction between the compounds (Greco et al.
1995). The concentration of the mixture causing x% inhibition
(ICxmix) is calculated from the ICx for each individual compound i
(ICxi) leading to the same response X and the relative molar contri-








If an ICx for themixture could not be derived due to incomplete
regression curves for the individual compounds (i.e., the individual
compounds did not reach an x% inhibition level; Figure 1), a worst-
case range of mixture predictions was estimated according to the
dose extrapolation approach for CA predictions (Scholze et al.
2014). To account for the statistical uncertainty in the CA predic-
tion, a combined Monte-Carlo (MC) and nonlinear regression
bootstrap simulation was conducted to establish approximate 95%
confidence limits around the predicted meanmixture response. For
each compound a distribution of resampled model fits was simu-
lated by parametric bootstrap with resamples drawn from the fitted
nonlinear (mixed) effect model (Faust et al. 2003), which then was
used as input for an MC to generate a distribution of mixture pre-
diction. Differences between predicted and observed mixture
effects were deemed statistically significant when the 95% confi-
dence belts of the prediction did not overlap with those of the
experimentally observedmixture effects.
Toxic Unit Summation
Under the assumption of CA, the ratio between the cmix and the con-
centration of the mixture expected to cause x% inhibition (ICxmix) is














with ci being the concentration of the ith compound in the mixture
(cmix = c1 +   + cn), TUi representing the toxic unit of the ith
compound (TUi = ci=ICxi), and TUsum representing the toxic units
summation. IfTUsum equals 1, themixture concentration is expected
to produce x% inhibition; if it is smaller or greater, the observable in-
hibition should be smaller or greater, respectively, although no
quantitative expectation on the effect size can be provided.
Ki Estimation
For each individual inhibitor, its IC20 value in the bioassay was
converted into a Ki value (i.e., the dissociation constant of the
inhibitor–TTR complex), according to
Ki =
Kd × PL20½ × IC20
L20½ × PI20½  − P20½ , (4)
where [PL20] is the concentration of protein–ligand complex, which
is 20% lower than in the absence of inhibitor, and with [L20], [PI20],
[P20] being the corresponding concentrations of free ligand, protein–
inhibitor complex, and free protein, respectively. Derivation of
Equation 4 and estimation of [L20], [PI20], and [P20] are described in
detail in “S1.4 Derivation ofKi from the ICx determined in the bioas-
say” in the Supplemental Material, based on Nikolovska-Coleska
et al. (2004). The 20% inhibition level was chosen because robust
IC20 values could be established for all compounds in the test set.
Similar Ki calculations were made for mixtures reflecting me-
dian or high-end concentrations in maternal and infant blood
from Nordic countries (see Excel Tables S1 and S2). The under-
lying IC20 values of these mixtures in the bioassay were calcu-
lated based on concentration addition (Equation 2) using the
molar proportions of the constituents in the different mixtures
considered (see Table S2).
Extrapolation to Human Blood
The degree by which the different inhibitor mixtures inhibit FITC-
T4 binding to TTR in vitro cannot be directly translated into in vivo
inhibition levels for TTR-T4 binding in human blood, because the
assay makes use of a fluorescent FITC-T4 probe, and not T4.
Moreover, T4 in human blood not only forms a protein–ligand
complexwith TTR, but also with other proteins, of which TBG and
ALB have highest T4-binding capacity (Salvatore et al. 2016).
In the absence of inhibitor, three protein–ligand equilibria are
in place that determine the degree of T4-TTR binding, that is,
KdP=
L½ × P½ 
PL½  ð5Þ
KdX=
L½ × X½ 
XL½  ð6Þ
KdY =
L½ × Y½ 
YL½  ð7Þ
where
[L] is the concentration of free ligand (i.e., T4 in blood);
[P], [X], and [Y] are the concentrations of unbound TTR,
TBG, and ALB, respectively;
[PL], [XL], and [YL] are the concentrations of the protein–
ligand complex TTR-T4, TBG-T4, andALB-T4, respectively;
KdP, KdX, and KdY are the dissociation constants of the protein–
ligand complex for TTR, TBG, andALB, respectively.
In the presence of inhibitor I, an additional equilibrium reac-
tion is in place for the inhibitor–TTR complex, that is,
KiP=
I½ × P½ 
PI½  (8)
where KiP is the dissociation constant of the protein–inhibitor
complex for TTR, and [I] and [PI] are the concentrations of the
free inhibitor and the inhibitor–TTR complex, respectively.
In addition to these four equilibrium reactions, the following
five mass balances are in place:
½LT = ½L+ ½PL+ ½XL+ ½YL ð9Þ
½PT = ½P+ ½PL+ ½PI ð10Þ
½XT = ½X+ ½XL ð11Þ
½YT = ½Y+ ½YL ð12Þ
½IT = ½I+ ½PI ð13Þ
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with [XT ], [YT ], and [IT ] being the total concentration of ligand
TBG, ALB, and inhibitor, respectively. For the known parame-
ters in these equations, estimates for [LT ], [PT ], [XT ], and [YT ] in
pregnant women and infants and for human KdX and KdY were
obtained as mean or median values reported in the literature (see
Table S3), whereas estimates for KdP and KiP and for [IT ] in
maternal and infant blood were obtained from the present study
(Tables 1 and 2, respectively). The remaining five unknown pa-
rameters (i.e., the free concentrations [L], [P], [X], [Y], and [I])
were then estimated by solving the five mass balances after rear-
rangements of Equations 9–13 with Equations 5–8. The actual
rearrangements as well as themethod for solving themass balances
are described in detail in “S1.5 Extrapolation to human blood –
Solving the fivemass balances” in the SupplementalMaterial.
Finally, the inhibition level of T4-TTR binding in human
blood was determined by comparing the estimated [PL] in the
presence of the inhibitor mixture to the estimated [PL] in the ab-
sence of inhibitor mixture (i.e., ½IT =0).
Figure 1. Individual concentration–response curves for the 25 selected test compounds in the FITC-T4 TTR-binding assay. (A) Perfluoroalkyl carboxyl acids
(PFCA); (B) perfluoroalkyl sulfonic acids (PFSAs) and FOSA; (C) PCBs and PBDEs; (D) PCB metabolites and PBDE metabolites; (E) other phenols and propyl-
paraben. In each panel the concentration–response curve for the natural ligand T4 is displayed as a dashed curve (-- -). Note: 2,4,6,-TBP, 2,4,6-tribromophenol;
4-OH-CB-107, 4-OH-2,3,30,40,5-pentachlorobiphenyl; 4-OH-CB-187, 4-OH-2,20,3,40,5,50,6-heptachlorobiphenyl; 5-OH-BDE-47, 5-OH-2,20,4,40-tetrabromodi-
phenyl ether; 6-OH-BDE-47, 6-OH-2,20,4,40-tetrabromodiphenyl ether; 60-OH-BDE-99, 60-OH-2,20,4,40,5-pentabromodiphenyl ether; BDE-47, 2,20,4,40-tetrabro-
modiphenyl ether; BDE-99, 2,20,4,40,5-pentabromodiphenyl ether; CB-118, 2,30,4,40,5-pentachlorobiphenyl; CB-153, 2,20,4,40,5,50-hexachlorobiphenyl; FITC,
fluorescein 5-isothiocyanate; FOSA, perfluorooctane sulfonamide; PCB, polychlorinated biphenyl; PDBE, polybrominated diphenyl ether; PFBS, perfluorobutane
sulfonic acid; PFDA, perfluorodecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxA, perfluorohexanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, per-
fluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid; T4, thyroxine; TBBPA, tetrabromo-
bisphenol-A; TTR, transthyretin.
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Contribution of Test Compounds to TTR-Binding
Potency of Dust
For 16 of the 25 compounds tested in this study, a concentration
qi (mol/g dust) in the SRM2585 dust sample could be retrieved
from the NIST Certificate of Analysis (NIST 2018), and from
open literature (see Table S4). For each of these 16 compounds,
its TTR-binding potency in the FITC-T4 binding assay relative






The combined TTR-binding potency of the 16 contaminants
in the SRM2585 sample was expressed as a calculated T4-equiva-





Upon testing its extract in the FITC-T4 binding assay, the TTR-
binding potency of the SRM2585 dust sample was expressed as
IC20dust, that is, the dust concentration (g dust/L) corresponding to
the extract concentration causing 20% inhibition in the assay.
IC20dust was converted into a T4-equivalent concentration in dust
[qT4EQtest] (mol/g dust) according to
qT4EQtest½ = IC20T4IC20dust : (16)
Finally, the contribution of the 16 compounds to the overall
TTR-binding potency of the SRM2585 extract was determined
by comparing [qT4EQcalculated] to [qT4EQtest].
Results
Mixture Composition
To design a mixture that reflects the composition of TTR-binding
contaminants in house dust, infant serum, and maternal serum,




IC20 (M) [95% CI of IC20] IC50 (M) Ki (M)RM bb1 bb2 bb3 bbmin bmax
Thyroxine (T4) Logit −14:3 −2:05 0b 1 2:1× 10–8 [1:8× 10–8, 2:5× 10–8] 1:0× 10–7 3:2× 10–8c
PFHxA Logit −13:2 −2:50 0b 1 1:6× 10–6 [1:1× 10–6, 2:1× 10–6] 5:6× 10–6 3:4× 10–6
PFHpA Logit −14:0 −2:36 0b 1 3:0× 10–7 [2:4× 10–7, 3:8× 10–7] 1:2× 10–6 6:4× 10–7
PFOA Logit −23:3 −3:91 0b 1 4:9× 10–7 [3:2× 10–7, 7:4× 10–7] 1:1× 10–6 1:1× 10–6
PFNA Weibull −11:1 −1:79 0b 1 3:6× 10–7 [2:9× 10–7, 4:5× 10–7] 1:1× 10–6 7:7× 10–7
PFDA Weibull −9:28 −1:69 0b 1 1:7× 10–6 [1:4× 10–6, 2:2× 10–6] 5:4× 10–6 3:7× 10–6
PFUnDA Logit −15:6 −2:84 0b 1 1:0× 10–6 [6:1× 10–7, 1:6× 10–6] 3:1× 10–6 2:2× 10–6
PFBS Logit −11:2 −2:24 0b 1 2:3× 10–6 [1:7× 10–6, 3:3× 10–6] 9:7× 10–6 5:1× 10–6
PFHxS Logit −16:7 −2:63 0b 1 1:4× 10–7 [9:7× 10–8, 1:9× 10–7] 4:6× 10–7 2:8× 10–7
PFOS Weibull −11:8 −1:73 0b 1 8:2× 10–8 [6:2× 10–8, 1:1× 10–7] 2:5× 10–7 1:6× 10–7
FOSA Logit −14:6 −2:38 0b 1 1:9× 10–7 [1:3× 10–7, 2:7× 10–7] 7:3× 10–7 4:0× 10–7
Propylparaben G.logit I −16:3 −3:18 0.454 0b 1 5:5× 10–6 [3:8× 10–6, 7:2× 10–6] 1:9× 10–5 1:2× 10–5
4-Nonylphenol Weibull −12:7 −2:21 0.433 1 1:8× 10–6 [1:2× 10–6, 2:7× 10–6] 1:6× 10–5 3:9× 10–6
Pentachlorophenol Logit −18:4 −2:55 0b 1 1:7× 10–8 [1:1× 10–8, 2:8× 10–8] 6:0× 10–8 2:4× 10–8
Triclosan Weibull −12:7 −2:08 0b 1 4:4× 10–7 [3:4× 10–7, 5:9× 10–7] 1:1× 10–6 9:3× 10–7
TBBPA Weibull −17:0 −2:23 0b 1 1:4× 10–8 [1:2× 10–8, 1:8× 10–8] 3:4× 10–8 1:7× 10–8
2,4,6-TBP Logit −20:5 −2:71 0b 1 8:9× 10–9 [6:9× 10–9, 1:1× 10–8] 2:9× 10–8 5:5× 10–9
BDE-47 G.logit II −20:2 −1:07 7:74× 105 0b 1 2:1× 10–7 [1:4× 10–7, 3:1× 10–7] 1:3× 10–6 4:4× 10–7
5-OH-BDE-47 Logit −36:9 −4:87 0b 1 1:4× 10–8 [8:7× 10–9, 2:1× 10–8] 2:7× 10–8 1:6× 10–8
6-OH-BDE-47 Logit −19:7 −2:8 0b 1 3:1× 10–8 [2:4× 10–8, 4:2× 10–8] 9:8× 10–8 5:4× 10–8
BDE-99 Logit −44:5 −6:29 0.514 1 7:3× 10–8 [5:6× 10–8, 8:9× 10–8] —g 1:5× 10–7
6 0-OH-BDE-99 Logit −28:3 −3:68 0b 1 8:4× 10–9 [5:5× 10–9, 1:2× 10–8] 2:0× 10–8 4:5× 10–9
CB-118 G.logit I −32:8 −4:72 0.209 0b 1 1:6× 10–7 [1:2× 10–7, 2:0× 10–7] 5:6× 10–7 3:2× 10–7
4-OH-CB-107 G.logit I −14:7 −3:71 1:04× 105 0b 1 3:4× 10–8 [2:5× 10–8, 4:5× 10–8] 6:8× 10–8 5:9× 10–8
CB-153 Logit −30:6 −4:45 0.234 1 7:7× 10–8 [6:3× 10–8, 9:2× 10–8] 1:8× 10–7 1:5× 10–7
4-OH-CB-187 Logit −35:4 −4:55 0b 1 8:2× 10–9 [5:4× 10–9, 1:2× 10–8] 1:7× 10–8 4:0× 10–9
SRM2585 Logit −1:19 −2:13 0b 1 6:2× 10–2d [4:1× 10–2, 8:9× 10–2]d 2:8× 10–1d NAe
Mixtures
Maternal Logit −18:9 −2:72 0b 1 3:7× 10–8 [2:5× 10–8, 5:4× 10–8] 1:8× 10–7f 6:7× 10–8
Infant Logit −19:2 −2:75 0b 1 3:3× 10–8 [2:4× 10–8, 4:4× 10–8] 1:3× 10–7f 5:7× 10–8
House dust Logit −14:9 −2:50 0b 1 3:2× 10–7 [2:2× 10–7, 4:6× 10–7] 1:5× 10–6f 6:8× 10–7
Note: 2,4,6,-TBP, 2,4,6-tribromophenol; 4-OH-CB-107, 4-OH-2,3,3 0,4 0,5-pentachlorobiphenyl; 4-OH-CB-187, 4-OH-2,2 0 ,3,4 0,5,5 0,6-heptachlorobiphenyl; 5-OH-BDE-47, 5-OH-
2,2 0,4,4 0-tetrabromodiphenyl ether; 6-OH-BDE-47, 6-OH-2,2 0,4,4 0-tetrabromodiphenyl ether; 6 0-OH-BDE-99; 6 0-OH-2,2 0,4,4 0,5-pentabromodiphenyl ether; BDE-47, 2,2 0,4,4 0-tetra-
bromodiphenyl ether; BDE-99, 2,2 0 ,4,4 0,5-pentabromodiphenyl ether; CB-118, 2,3 0 ,4,4 0,5-pentachlorobiphenyl; CB-153, 2,2 0,4,4 0,5,5 0-hexachlorobiphenyl; CI, confidence interval;
FITC, fluorescein 5-isothiocyanate; FOSA, perfluorooctane sulfonamide; IC20, 20% inhibitory concentration; IC50, 50% inhibitory concentration; Ki , protein–inhibitor dissociation
constant; NA, not applicable; PFBS, perfluorobutane sulfonic acid; PFDA, perfluorodecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxA, perfluorohexanoic acid; PFHxS, per-
fluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid; RM, regression
model; SRM2585, Standard Reference Material® 2585 house dust extract; T4, thyroxine; TBBPA, tetrabromo-bisphenol-A; TTR, transthyretin.
aMathematical regression model as defined by Scholze et al. (2001): bb1,bb2,bb3,bbmin estimated model parameters, given for concentrations expressed in M (rounded values), bmax were
not estimated, but set to 1 relating to the mean value of the controls.
bHeld fixed.
cThe dissociation constant for the TTR-T4 complex was determined as a Ki value for T4 in the competitive binding experiments with ligand FITC-T4 and competitor T4 but was
applied as a Kd value for T4 in the extrapolation from the in vitro bioassay to the in vivo situation in human blood.
dIC20 and IC50 values for the SRM2585 house dust sample are expressed in g dust/L, not in M.
eThe Ki value for house dust cannot be calculated given that it should be expressed in mol/L, not in g/L.
fDerived from the toxic unit extrapolation method by Scholze et al. (2014): the two worst-case toxic unit assumptions resulted into nearly identical estimation and thus are reported
only as single value.
g50% inhibition level was not reached for BDE-99 (see Figure 1).
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median concentrations of the test compounds in these three differ-
ent matrices were collected from the open literature from studies
performed in Sweden or alternatively in a European, preferably
Nordic, country (see Excel Tables S1 and S2). Median concentra-
tions in house dust could be collected for 18 of the 25 selected com-
pounds (see Excel Table S1). This excluded the five hydroxylated
PBDE and PCBmetabolites, which are not expected to be found in
house dust, and FOSA and nonylphenol, which have been reported
in Swedish serum but had very low detection frequency in
European house dust.Median concentrations in human serumwere
collected for 22 compounds, that is, 21 in maternal serum and 20 in
infant serum (see Excel Table S1). No median human serum levels
could be retrieved for PFHxA, PFUnDA, and PFBS from Swedish,
Nordic, or European studies. At the time of performing the litera-
ture search, very few studies had actually looked for these PFASs
in human serum. Therefore, it was decided to include these three
compounds in the dust mixture to address a more complete PFAS
exposure profile to humans.
Mixtures reflecting median concentrations in house dust, mater-
nal, and infant serumwere dominated by only a few of the test com-
pounds. In fact, >80% of the molar mixture composition could be
attributed to 2 of 18 compounds in the reconstituted dust mixture
(i.e., propylparaben and triclosan), 4 of 21 compounds in the reconsti-
tuted maternal serum mixture (i.e., PFHxS, PFOS, pentachlorophe-
nol, and PFOA), and 3 of 20 compounds in the reconstituted infant
serum (i.e., PFOS, pentachlorophenol, and PFOA). Compositions of
the reconstituted maternal and infant serum mixtures were similar,
and differed considerably from the house dust mixture. The exact
compositions of the reconstituted mixtures tested in the TTR-binding
assay are provided in Table S1.
TTR-Binding by Individual Compounds
From the saturation experiment with 30 nM TTR and a concen-
tration series of FITC-T4, a Kd value of 140 nM was determined
for the FITC-T4-TTR complex. For all individual test compounds
a concentration-dependent displacement of FITC-T4 from the
TTR protein was observed in the competitive binding experi-
ments (Figure 1), confirming earlier studies with a radioligand
binding assay (RLBA) (see Excel Table S1). All concentration–
response models as well as the estimates for their IC20, IC50, and
Ki values are provided in Table 1. As was to be expected based
on structural similarities with T4 and on previously reported
RLBA results, 2,4,6-TBP, pentachlorophenol, TBBPA (Figure 1E),
and themetabolites of PBDEs and PCBs (Figure 1D) had the highest
competitive potency to displace FITC-T4 from the TTR protein. In
fact, these halogenated phenols all had higher competitive binding
potencies than the endogenous ligand T4 itself. The PFASs had
TTR-binding potencies lower than T4 (Figure 1A,B), with the high-
est potencies found for PFOS. Remarkably, the parent PBDE and
PCB compounds also showed competitive binding to TTR, but
at high test concentrations the maximum competitive potency of
BDE-99 and PCB-153 leveled off before reaching complete inhibi-
tion (Figure 1C). In the RLBA, only very weak TTR-binding po-
tency had been observed for the parent PBDE and PCB compounds.
Altogether, a Pearson’s correlation coefficient of r=0:87 was
observed between log-transformed IC50 values determined in the
competitive binding assay with FITC-T4 (the present study) and log-
transformed IC50 values previously reported (see Excel Table S1) for
the competitive binding assaywith radiolabeled T4 (see Figure S1).
TTR-Binding by Reconstituted Mixtures
For all three mixtures, a concentration-dependent decrease in TTR-
binding by FITC-T4 was observed, reaching 100% displacement at
the highest test concentrations (Figure 2). For each mixture, the
concentration–response curve fitted on the measured data over-
lapped with the confidence intervals of the concentration–response
curve calculated according to concentration addition, indicating that
TTR-binding of complexmixtures can indeed be approximatedwell
by the concentration addition principle.
The combined median concentrations actually reported in
maternal or infant serum from Nordic countries approached the
IC20 determined for the experimentally tested mixtures (i.e.,
TUsum  1) (Figures 2 and 3; Table 2). According to the princi-
ple of concentration addition, concentration response curves and
corresponding IC20 values were calculated for the nontested mix-
tures reflecting high-end concentrations in maternal and infant se-
rum. For these mixtures, the combined high-end concentrations
exceeded the predicted IC20 in the bioassay by a factor >3 (i.e.,
TUsum = 3:5 and TUsum = 4:0 for the maternal and infant mixture,
respectively; Table 2).
Table 2. Total concentrations and corresponding TTR-binding potencies of mixtures consisting of median or high-end concentrations determined in maternal
and infant serum from Nordic countries as measured in the in vitro binding assay and as extrapolated to human blood.
Parameter
Maternal mixture based on Infant mixture based on
Median concentrations High-end concentrations Median concentrations High-end concentrations
Total inhibitor concentration in blood (M) 5:1× 10–8 2:5× 10–7 4:0× 10–8 1:3× 10–7
IC20 predicted in bioassay (M)
(95% confidence interval)
5:7× 10–8
[4:2× 10–8, 7:2× 10–8]
7:3× 10–8
[5:3× 10–8, 9:5× 10–8]
3:9× 10–8
[2:7 × 10–8, 5:5× 10–8]
3:1× 10–8
[2:1× 10–8, 4:5× 10–8]
TUsum in blood based on IC20 in bioassay 0.89 3.5 1.0 4.0
Ki (predicted in the bioassay) (M) 1:1× 10–7 1:5× 10–7 7:1× 10–8 5:4× 10–8
Fraction of TTR in blood occupied by T4 (%)
Without inhibitor mixture 0.11 0.11 0.085 0.085
With inhibitor mixture 0.10 0.099 0.084 0.081
Fraction of T4 in blood bound to TTR (%)
Without inhibitor mixture 3.1 3.1 1.7 1.7
With inhibitor mixture 3.0 2.9 1.7 1.6
Inhibition in T4-TTR binding in blood
compared with situation without inhib-
itor mixture (%)a
1.3 6.2 1.5 4.9
IC20 in blood (M) 8:0× 10–7 8:1× 10–7 5:2× 10–7 5:1× 10–7
TUsum in blood based on IC20 in blood 0.063 0.31 0.077 0.24
Margin of exposure to IC20 in blood 16 3.2 13 4.1
Note: All estimates are based on predicted IC20 values calculated according to the principle of concentration addition. The corresponding estimates for the different blood parameters
used to make these calculations (i.e., total levels of T4, TTR, TBG, ALB, and Kd values for the T4-TTR, T4-TBG, and T4-ALB complexes) are provided in Table S3. ALB, albumin;
CI, confidence interval; IC20, 20% inhibitory concentration; Ki , protein–inhibitor dissociation constant; T4, thyroxine; TBG, thyroid hormone binding globulin; TTR, transthyretin;
TUsum, Toxic Unit summation.
aSee Figure 4.
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More than 80% of the inhibition caused by the reconstituted
house dust mixture could be attributed to 5 of the 18 compounds
present in the mixture, that is, triclosan, TBBPA, BDE-99, penta-
chlorophenol, and 2,4,6-TBP. For the reconstituted maternal and
infant serum mixtures this was the case for even fewer com-
pounds, that is, 3 of 21 (pentachlorophenol, PFOS, and PFHXs)
and 2 of 20 compounds (pentachlorophenol and PFOS), respec-
tively (see Figure 3).
TTR-Binding by House Dust Extract
For the 16 compounds tested in the present study and analyzed in
the SRM2585 dust sample, a summarized T4-equivalent concen-
tration was calculated of 4:0 nmol=g dust (see Table S4). In the
TTR-binding assay, the SRM2585 extract showed a concentration-
dependent displacement of FITC-T4, with IC20dust = 0:062 g
dust/L (Table 1). Using the IC20 for T4 (Table 1), the T4EQ con-
centration of the SRM2585 dust sample was estimated to be
21=0:062= 340 nmol=g dust (Equation 16). Consequently, the 16
compounds for which concentrations were available could only
explain 4:0=340= 1:2% of the totally measured TTR-binding
potency.
Extrapolation to Human Blood
Using the dissociation constants for the T4-TTR ligand–protein
complex (Table 1; this study) and for the T4-TBG and T4-ALB
ligand–protein complexes as well as the median or mean total T4
levels determined in normal adult, maternal, or infant blood
reported in literature (see Table S3), >99% of the total T4 con-
centration in human blood was calculated to bind to the TH bind-
ing proteins in the absence of inhibitors. The corresponding TTR/
TBG/ALB distribution was estimated to be 6/76/18% in normal
adult blood. During the first trimester of pregnancy, when the fe-
tus depends completely on the maternal TH supply, the calculated
TTR/TBG/ALB distribution in maternal blood shifts in the direc-
tion of TBG (i.e., 3/87/10%), due to increased TBG levels and
decreased TTR and ALB levels compared with normal levels
(see Table S3). Also for infants, the calculated TTR/TBG/ALB
distribution is more dominated by TBG than in normal adults
(i.e., 4/90/6%), due to higher TBG and lower TTR and ALB con-
centrations than reported for normal adults (see Table S3).
In maternal blood, the mixture of inhibitors reflecting median
concentrations was estimated to cause a 1.3% inhibition in T4-TTR
binding compared with the uninhibited situation. In infant blood,
the median mixture of inhibitors was estimated to cause a 1.5% in-
hibition in T4-TTR binding (Table 2; Figure 4). At high-end inhibi-
tor concentrations, 6.2% inhibition was estimated in maternal
blood and 4.9% in infant blood. Consequently, the median or high-
end concentrations in maternal or infant blood were lower than the
inhibitor concentrations expected to cause 20% in vivo inhibition in
human blood (i.e., TUsum < 1), butmargins of exposurewere small,
ranging from 13 to 16 for median concentrations and from 3.2 to
4.1 for high-end concentrations (Table 2).
Discussion
The goal of the present study was to determine the TTR-binding
potency of reconstituted mixtures of house dust contaminants as
present in maternal serum, infant serum, and house dust. In addi-
tion, we investigated whether this potency could be predicted
according to the principle of concentration addition. Similar
TTR-binding potencies were observed for the mixtures reflecting
median concentrations in maternal and infant serum in terms of
IC20 values (37 and 33 nM, respectively), IC50 values (180 and
130 nM), and corresponding Ki values (67 and 57 nM). The
house dust mixture was less potent (i.e., IC20 = 320 nM,
IC50 = 1:5 lM, Ki = 680 nM), due to differences in composition
between both serum and house dust mixtures (see Table S1).
A major part (i.e., >80%) of the observed inhibition of FITC-
T4 binding to TTR could be attributed to a minor part (i.e., <20%)
Figure 2. Concentration–response curves for the reconstituted mixtures
based on the ratio of median concentrations reported in (A) house dust, (B)
maternal serum, and (C) infant serum from Nordic countries. The vertical
gray bar in plots B and C indicates the mixture concentration reflecting the
median concentration of the individual compounds actually detected in
maternal or infant blood samples from Nordic countries. Note: CA, concen-
tration addition; CI, confidence interval; FITC, fluorescein 5-isothiocyanate;
T4, thyroxine; TTR, transthyretin; TU, Toxic Unit.
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of the compounds present in the mixture. These results support
Pareto’s principle that 80% of the outcome can be explained by
only 20% (or less) of the causal factors. Similar results were previ-
ously found in an androgen-receptor (AR) antagonistic reporter
gene assay with mixtures consisting of 22 anti-androgenic com-
pounds that were reconstituted according to their proportion in av-
erage and high-end serum levels (Kortenkamp et al. 2014). In our
TTR-binding assay, pentachlorophenol and TBBPA were driving
compounds (i.e., explaining a significant amount of the observed
TTR-binding capacity) in all three mixtures. Some compounds,
however, were driving the TTR-binding potency in one reconsti-
tuted mixture but not in the other, like PFOS in both human serum
mixtures, PFHxS and 4-OH-CB-187 more particular in the mater-
nal serum mixture, and triclosan and propylparaben in the house
dust mixture.
For the mixtures based on median blood levels, the actual me-
dian concentrations in blood were in the same range as the corre-
sponding IC20 values determined in the bioassay (i.e., TUsum  1).
In previous studies, the OH-PBDEs in blood from children working
onNicaraguan e-waste sites were estimated to contain TTR-binding
Figure 3. Cumulative plots showing the predicted TTR-binding potency of house dust contaminants or their metabolites at median concentrations reported in
(A) maternal and (B) infant serum in Nordic countries. Compounds are ranked according to their contribution to the total TTR-binding potency of the mixture,
predicted on the basis of the concentration addition principle. The y-axes represent the Toxic Unit summation (TUsum), i.e., the sum of ranked ratios of the
compounds’ concentration and its IC20 value. Note: 2,4,6,-TBP, 2,4,6-tribromophenol; 4-OH-CB-107, 4-OH-2,3,3 0,4 0,5-pentachlorobiphenyl; 4-OH-CB-187,
4-OH-2,2 0,3,4 0,5,5 0,6-heptachlorobiphenyl; 5-OH-BDE-47, 5-OH-2,2 0,4,4 0-tetrabromodiphenyl ether; 6-OH-BDE-47, 6-OH-2,2 0,4,4 0-tetrabromodiphenyl ether;
6 0-OH-BDE-99; 6 0-OH-2,2 0,4,4 0,5-pentabromodiphenyl ether; BDE-47, 2,2 0,4,4 0-tetrabromodiphenyl ether; BDE-99, 2,2 0,4,4 0,5-pentabromodiphenyl ether;
CB-118, 2,3 0,4,4 0,5-pentachlorobiphenyl; CB-153, 2,2 0,4,4 0,5,5 0-hexachlorobiphenyl; FOSA, perfluorooctane sulfonamide; IC20, 20% inhibitory concentration;
PFBS, perfluorobutane sulfonic acid; PFDA, perfluorodecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxA, perfluorohexanoic acid; PFHxS, perfluorohex-
ane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid;
TBBPA, tetrabromo-bisphenol-A; TTR, transthyretin.
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potency equivalent to 0:55 nM T4 (Hamers et al. 2008). Similarly,
the PFAS compounds in blood from European and North American
adults were estimated to have TTR-binding potency equivalent to
3.1 and 5:1 nM T4, respectively (Weiss et al. 2009). Given the IC20
of approximately 30 nM determined for T4 in the radioligand bind-
ing assay used in these studies, the observed T4 equivalent concen-
trations correspond to TUsum = 0:018 for OH-PBDEs and to
TUsum = 0:10 to 0.17 for PFAS. These values are very much in line
with the contribution of these compounds to the overall TTR-
binding capacity determined in the present study (Figure 3).
The mixtures reflecting actual high-end concentrations in
maternal and infant blood exceeded the IC20 predicted for the bio-
assay by a factor of 3.5 and 4.0, respectively. The relatively small
difference in toxic potencies between the median and the high-end
concentration mixtures is due to the fact that no maximum
concentrations were reported for many compounds. Instead, we
used the 95th percentile from reported serum concentrations as a
proxy for the maximum concentration, which implies that 5% of
the population is expected to have even higher serum concentra-
tions. For the PFAS compounds, high-end concentrations in mater-
nal serum were estimated using a conservative ratio between the
maximum and an average level of 3, based on PFASmeasurements
in a Spanish study (Manzano-Salgado et al. 2015). Altogether,
ratios between high-end and median concentrations for most TTR-
binding compounds ranged from <2 to 10, except for triclosan
(both maternal and infant); PFHxS, PFOS, and TBBPA (infant);
and propylparaben (maternal) (see Excel Tables S1 and S2).
The finding that median concentrations in blood correspond to
IC20 levels in the bioassay cannot be directly translated to the actual
in vivo inhibition of T4-TTR binding in human blood at similar
Figure 4. Estimated concentration–response curves in human blood for mixtures representing median concentrations or high-end concentration of house dust
contaminants reported in human (A) maternal or (B) infant serum from Nordic countries. The vertical dashed lines indicate the actual median (left) and high-
end (right) concentration found in serum, and the corresponding horizontal dashed lines indicate the concentration of the TTR-T4 complex (top and bottom rep-
resent median and high-end respectively). The black arrows indicate the IC20 level estimated for serum, which overlap for the two dose–response curves in
both panels, i.e., 8:0× 10–7 M (median) and 8:1× 10–7 M (high-end) for the maternal mixtures and 5:2× 10–7 M (median) and 5:1× 10–7 M (high-end) for the
infant mixtures (Table 2). IC20, 20% inhibitory concentration; T4, thyroxine; TTR, transthyretin.
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inhibitor concentrations. After all, the bioassay makes use of a
fluorescent-labeled FITC-T4 probe (and not T4 itself), which is
tested in an overdose (i.e., ½FITC-T4=110 nM) compared with the
only TH binding protein present in the assay (i.e., ½TTR=30 nM).
Under physiological conditions, T4 is indeed present at similar con-
centrations as FITC-T4 in the assay, but TTR is complemented by
two other T4-binding proteins (i.e., TBG and ALB), whereas all
three T4-binding proteins are present at much higher concentrations
than the TTR concentration in the bioassay [see Table S3). Using
values from the literature for T4 concentration and dissociation con-
stants, [i.e., ½T4=107 nM, KdðTTRÞ=14:3, KdðTBGÞ=0:100,
KdðALBÞ=1,430 nM (Salvatore et al. 2016)], a 12/71/17% distri-
bution of T4 over TTR/TBG/ALB was calculated. This distribution
is very similar to the 11/74/15% distribution calculated by Schussler
(2000) based on free T4 rather than total T4 concentrations and to
the 15/75/10% distribution traditionally believed to be present in
blood (e.g., Richardson2007), although it is unclearwhether this lat-
ter distribution was actually calculated or measured. Using the dis-
sociation constant determined in the present study for the TTR-T4
complex (i.e.,Kd = 32 nM; Table 1), however, the distribution of T4
over TTR/TBG/ALB in blood was calculated to be 6/76/18%. The
difference between both dissociation constants for the TTR-T4 com-
plex reported in the literature and determined in the present study
may be due to differences in experimental temperatures, that is,
37°C (Robbins and Edelhoch 1986) and 4°C (the present study),
although temperature did not seem to affect the T4 binding in our
binding assay (see Figure S2). The 4°C temperature was chosen in
order to resemble previous studies with radioligand binding assays
performed at this temperature (e.g., Hamers et al. 2008; Weiss et al.
2009; Zhang et al. 2015). Alternatively, the difference may be
explained by the different methods used to establish the dissociation
constant. Although the method used to determine the Kd = 14:3 nM
is not clear, it must be different from the method used in the present
study given that the fluorescent FITC-T4 probe was not described
before 2012 (Ren and Guo 2012). Still, both Kd values fit very well
within the span of other Kd values reported in the literature ranging
from Kd = 5 nM determined at unknown temperature (Feldt-
Rasmussen and Rasmussen 2007) to Kd = 84 nM determined at
25°C (Purkey et al. 2001). Therefore, we have used the Kd value
determined in the present study to estimate the in vivo inhibition for
the human situation. Thus, the dissociation constant for the TTR-T4
complex was directly comparable to the dissociation constant for the
inhibitor–TTR complex determined at the same temperature (4°C).
Using these latter dissociation constants (i.e., Ki values),
T4-binding to TTR in blood was estimated to be inhibited by 1.3–
1.5% by the mixture of house dust contaminants at median con-
centration levels (Table 2). The relevance of this T4 displacement
from TTR in humans remains to be clarified. For the majority of
the TTR-binding compounds considered in the present study,
rodent studies have found a decrease in circulating total T4 levels
in serum or plasma (see, for instance, reviews by EFSA 2005,
2011b, 2011a, 2018). The decrease is attributed to the fact that T4
displaced from TTR is freely available for hepatic uptake and
conjugation followed by biliary elimination. This increased he-
patic clearance is further enhanced by the fact that many of the
test compounds can activate nuclear CAR and PXR receptors,
causing an induction of hepatic phase II enzymes responsible for
glucuronidation or sulfation of T4. Animal studies with PBDEs,
PCBs, and PFASs have further indicated that decreased maternal
levels of circulating T4 are associated with neurodevelopmental
effects on cognitive function, motor activity, and behavior in off-
spring (EFSA 2005, 2011b, 2011a, 2018). In humans, however,
the situation is less clear. For the compounds considered in the
present study, some studies have reported negative associations
with T4 levels in blood (DH Kim et al. 2016; Makey et al. 2016;
Zheng et al. 2017; Zota et al. 2011), but other studies have
reported positive associations (EFSA 2011a; Shrestha et al. 2017;
Stapleton et al. 2011), concentration-dependent associations
(Zhao et al. 2015), or a lack of associations (Audet-Delage et al.
2013; Kato et al. 2016; Olsen et al. 2003). The observed differ-
ence between rodent and human studies is attributed to the fact
that humans have a reserve of T4 stably bound to TBG. In
rodents, however, TBG is not found at the age they are usually
tested for in animal studies (Lewandowski et al. 2004; Vranckx
et al. 1990). As a consequence, rodents have a faster T4 turnover
than humans [half-life times of 12–24 h compared with 5–9 d,
respectively (Jahnke et al. 2004)] and are considered to be more
sensitive than humans to changes in TH balance by T4 displace-
ment from TTR or by induced hepatic clearance.
The higher binding affinity of T4 for TBG than for TTR and
ALB,which is also reflected by the TTR/TBG/ALBbinding propor-
tions calculated above, could be taken to suggest that TTR-binding
in human blood ismuch less important than TBG-binding. This sug-
gestion, however, is too simplistic because the actual relevance of
TTR-binding is most likely not in the circulation of T4 but in the
delivery of free T4 hormone to the target cells, which depends on the
dissociation rate (koff) of the TTR-T4 complex and the capillary
transit time (Richardson 2007). The dissociation rates for T4 from
the different TH binding proteins range from koff = 0:017 s−1 for
TBG, via koff = 0:080 s−1 for TTR, to koff > 0:5 s−1 for ALB
(Mendel et al. 1988). Given the capillary transit time in different tis-
sues (Mendel 1989), the contribution of the TTR-T4 complex to the
free T4 pool equals that of the TBG-T4 complex (Robbins 2002). As
such, the late Sidney Ingbar, a specialist in thyroid endocrinology,
considered TBG as the saving account for T4 and TTR as the check-
ing account (Robbins 2002). In the same context, others drew a par-
allel to the Goldilocks principle, that is, TBG binds T4 too tightly for
delivery of free T4 to target cells, ALB binds T4 too loosely, and
TTR binds T4 just right (Alshehri et al. 2015). Consequently, inhibi-
tion of TTR-T4 binding by xenobiotic compounds may interfere
with the level of T4 delivery at the target tissue.
TTR is also known to play a role in the T4 transport across at
least two barriers in distribution, that is, the placenta and the
blood-cerebrospinal-fluid barrier (BCSFB) (Landers and Richard
2017; Richardson et al. 2015). Both barriers are known to synthe-
size endogenous TTR. After excretion into the maternal blood
circulation (i.e., apical side), placental TTR binds T4 upon which
the TTR-T4 complex passes the placenta and is thought to be
finally delivered at the fetal capillaries (Landers and Richard
2017). TTR produced by the choroid plexus epithelial cells is not
excreted to the blood-facing (basolateral) side but, rather, binds
intracellularly to the T4 taken up by the cells and is then excreted
into the cerebrospinal fluid, where it is distributed to the brain
(Richardson et al. 2015). This transcellular route across the
BCSFB seems especially relevant for TH transport to the devel-
oping brain (Johansson et al. 2008). The possible effect of TTR-
binding xenobiotic compounds on the transport of TH across
these barriers is a subject for further studies. In our opinion, such
studies should also include the transport of the TTR-binding
xenobiotics across these barriers.
Despite TTR’s role in the delivery of TH at the target tissue,
and the transport of TH across the barriers, an association between
maternal TTR malfunctioning and neurodevelopmental disorders
in children and infants has not been reported. TTR mutations in
humans have been associated with peripheral neuropathy due to
amyloid deposition (João and Saraiva 1995) but not to effects on
the developing brain due to TH deficiency. On the other hand, no
humans lacking TTR have been reported either. This suggests that
TTR’s role in transporting sufficient TH to the developing fetal
brain is crucial for survival. This hypothesis, however, was
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questioned when Episkopou et al. (1993) demonstrated that TTR-
null mice were viable, fertile, and without an overt TH-deficient
phenotype. Apparently, the absence of TTR-mediated TH trans-
port to the developing fetal brain was compensated by transmem-
brane transporter proteins such as monocarboxylate transporters
(e.g., Mct8) and organic anion transporting polypeptides (e.g.,
Oatp1c1). More recent studies, however, did report differences in
brain development between TTR-null and wild-typemice, that is, a
decrease in TH-dependent apoptosis of neural stem cells in the sub-
ventricular zone (Richardson et al. 2007) and a delay in TH-
regulated events in central nervous systemmaturation (Monk et al.
2013). It is not known whether such effects also occur in humans
andwhether they affect cognition in children and infants.
The predictive value of the estimated 1.3–1.5% inhibition of
T4-binding to TTR in human blood by house dust contaminants
at median concentration levels needs to be further put in perspec-
tive. So far, inhibitor binding to other proteins than TTR is not
considered simply because no Ki values for other proteins are
available. Inhibitor binding to other proteins may decrease the
concentration of free inhibitor and thereby its bioavailability to
compete with T4 for TTR binding. On the other hand, the inhibi-
tors may also bind to TBG and ALB and thereby compete for
their T4-binding capacity. The consequence of such binding for
T4 binding in general and for T4 delivery by TTR can only be
estimated if Ki values become available for the TBG-inhibitor
and ALB-inhibitor complexes.
Furthermore, many TTR-binding house dust contaminants are
not represented in the mixtures studied in the present paper,
because their presence in house dust or human blood is unknown or
because their TTR-binding potency is unknown. As shown for the
SRM2585 house dust sample, the 16 PFAS, PBDE, PCB and halo-
genated phenolic compounds for which concentrations were avail-
able only contributed 1.2% to the overall TTR-binding potency of
the house dust extract. This finding clearly illustrates that house
dust contains many more TTR-binding compounds than we cur-
rently know. Similarly, Kollitz et al. (2018) demonstrated that
house dust extracts significantly antagonized activation of the TH
receptor b ðTRbÞ by T3. TRb antagonistic activity was negatively
associated with free T4 levels in residents from the sampled houses
and positively correlated with the presence of 12 brominated or
organophosphorus flame retardants in the house dust. Because all
12 contaminants were inactive as TRb antagonists on an individual
basis, these results suggest either a synergistic mechanism or the
presence of unknownTRb antagonistic contaminants in house dust
co-occurring with the 12 flame retardants. Previous nontargeted
screening studies (Rager et al. 2016; Rostkowski et al. 2019) have
confirmed that house dust contains thousands of chemicals of
which the identity is unknown, let alone their TH disrupting
capacity. Still, the different patterns in major contributors to the
TTR-binding potencies in the mixtures reflecting known TTR-
binding compounds in human blood and house dust indicate that
dust is not the only route of human exposure to TTR-binding com-
pounds.Most likely, exposure through food also contributes signif-
icantly to levels of TTR-binding compounds in human blood.
Moreover, the present study focused on mixtures reflecting
median serum concentrations in Nordic countries. Especially for
PBDEs, it is well known that serum levels are 4–18 times higher
in North American than in European populations (Bramwell et al.
2016; Hites 2004; Huang et al. 2014). The contribution of the
PBDEs and their metabolites to the TTR-binding potency of the
reconstituted serum mixtures tested in the present study, how-
ever, was negligible (Figure 3). This finding did not change if
concentrations of PBDEs and their metabolites were multiplied
by a worst-case factor of 20. Given the fact that regional differen-
ces in serum concentrations are less obvious for the other
compounds included in the present study, the results obtained for
the Nordic mixtures are expected to be representative for other
regions as well.
As discussed above, no clear relationship has been found
between exposure to TTR-binding compounds and circulating T4
levels in humans. This may be due to the relatively small pre-
dicted effect size at median exposure levels, that is, 1.3–1.5% in-
hibition of T4-TTR binding (Table 2). Similarly, Audet-Delage
et al. (2013) found that concentrations of TTR-binding com-
pounds in Inuit women of childbearing age were not high enough
to affect TTR-mediated TH transport. Although this study popu-
lation was considered to have a relatively high dietary exposure
to persistent organic pollutants including PCBs, PBDEs, PFASs,
and pentachlorophenol, the reported plasma concentrations of
TTR-binding compounds in the Inuit women were in the same
range (i.e., PFOSs) or lower (i.e., OH-CBs and pentachlorophe-
nol) than the median concentrations in Nordic countries used for
reconstituting the median exposure level mixture in the present
study. Given the between-day variation in their TTR (11.9%) and
T4-TTR (19.7%) measurements (Audet-Delage et al. 2013), it is
to be expected that a predicted effect size in the same range or
lower than in the present study (i.e., 1.3% inhibition inT4-TTRbind-
ing in maternal blood; Table 2) could not be detected in the Inuit
women. We expect, however, that the absolute decrease in T4-TTR
binding corresponding to a relative decrease of 1.3–1.5% may have
more impact on circulating TH levels in humans with low T4 levels
than in humans with normal T4 levels. As such, we hypothesize that
the presence of TTR-binding house dust contaminants in blood may
especially aggravate the poor TH status in mothers with or prone
to developing hypothyroidism or hyperthyroxinemia during early
pregnancy, which is associated with impaired neurodevelopment in
their offspring (Fan and Wu 2016; Henrichs et al. 2013; Korevaar
et al. 2016;Morreale de Escobar 2003).
In conclusion, the TTR-binding potency of reconstituted mix-
tures of house dust contaminants was well described according to
the principle of concentration addition. Moreover, it followed
Pareto’s principle as >80% of the observed inhibition could be
explained by <20% of the compounds present in the mixture.
Based on the observed bioassay responses, the median concentra-
tions of house dust contaminants reported in maternal and infant
human serum in Nordic countries were estimated to cause a 1.3–
1.5% inhibition in T4-TTR binding in human blood. In the high-
end concentration range, these estimates even reached 4.9–6.2%
inhibition levels. This lack in margin of exposure toward TTR-
inhibiting concentrations in blood is unfavorable given the role of
TTR in delivery of TH to target tissues and its role in assisting TH
to cross the placenta and the BCSFB. Possibly, the estimated inhi-
bition levels may especially have impact on the developing fetal
brain in cases ofmaternal hypothyroidism or hypothyroxinemia.
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